Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man

Clinical Science

Volumn 90, Issue 3, 1996, Pages 205-213

  Schmitt, Francois ^a   Natov, Svetlozar ^a   Martinez, Frank ^a   Lacour, Bernard ^a   Hannedouche, Thierry P ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Angiotensin I receptor blockade; Angiotensin converting enzyme inhibition; Fractional dextran clearance; Glomerular filtration; Kidney tubule; Lithium clearance

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; DEXTRAN; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; LITHIUM; LOSARTAN POTASSIUM; RENIN; SODIUM; URIC ACID;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; GLOMERULUS FILTRATION; HUMAN; HUMAN EXPERIMENT; KIDNEY CIRCULATION; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RECEPTOR BLOCKING; SODIUM URINE LEVEL; URIC ACID URINE LEVEL; VASODILATATION;

EID: 0030061147     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0900205     Document Type: Article

References (42)

1. Ichikawa I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 1991; 40: 583-96.
2. Juillerat L, Nussberger J, Ménard J. et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990; 16: 564-72.
3. Mooser V, Nussberger J, Juillerat L, et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990; 15: 276-82.
4. Bao G, Gohlke P, Qadri F, Unger T. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension 1992; 20: 74-9.
5. Fenoy FJ, Scicli G, Carretero O, Roman R. Effect of an angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to captopril. Hypertension 1991; 17: 1038-44.
6. Kiowski W, Linder L, Kleinbloesem C, van Brummelen P, Bühler FR. Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition. Circulation 1992; 85: 1-8.
7. Jaiswal N, Diz DI, Chappell MC, Khosla MC, Ferrario CM. Stimulation of endothelial cell prostaglandin production by angiotensin peptides: characterization of receptors. Hypertension 1992; 19 (Suppl. II): II-49-55.
8. Pörsti I, Bara AT, Busse R, Hecker M. Release of nitric oxide by angiotensin-(I-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol 1994; III: 652-4.
9. 2 subtype-specific angiotensin II ligands. J Pharmacol Exp Ther 1992; 262: 1154-60.
10. Noth RH, Tan SY, Mulrow PJ. Effects of angiotensin II blockade by saralasin in normal man. J Clin Endocrinol Metab 1977; 45: 10-15.
11. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991; 83: 1333-42.
12. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-51.
13. Goldberg MR, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993; 21: 704-13.
14. Chang RS, Ueki IF, Troy JL, Deen WM, Robertson CR, Brenner BM. Permselectivity of the glomerular capillary wall to macromolecules. II. Experimental studies in the rats using neutral dextran. Biophys J 1975; 15: 887-906.
15. Hannedouche T, Schmitt F, Ikeni A, et al. Renal response to angiotensin after short-term angiotensin converting enzyme inhibition. Hypertension 1993; 21: 261-6.
16. Nelson E, Arcuri K, Ikeda L, Snavely D, Sweet CS. Efficacy and safety of losartan in patients with essential hypertension [Abstract]. Am J Hypertens 1992; 5: 19.
17. Munafo H, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992; 51: 513-21.
18. NaV in the rat during infusion of angiotensin. Am J Physiol 1969; 216: 554-8.
19. Thomsen K. Lithium clearance: a new method for determining proximal and distal tubular reabsorption of sodium and water. Nephron 1984; 37: 217-23.
20. Landis EM, Pappenheimer JR. Exchange of substance through the capillary walls. In: Hamilton WF, Dow P, eds. Handbook of physiology, section 2: circulation. Washington, DC: American Physiological Society, 1963, vol 2: 961-1034.
21. Bratton AC, Marshall EK. A new coupling component for sulfanilamide determination. J Biol Chem 1960; 128: 537-50.
22. Galli A, Jeanmaire J. Dosage colorimétrique de l'inuline dans le sang et dans les urines. Application à l'analyse automatique. Ann Biol Clin 1965; 23: 931-41.
23. Poulsen K, Jorgensen J. An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J Clin Endocrinol Metab 1984; 39: 816-25.
24. Ronca-Testoni S. Direct spectrophotometric assay for angiotensin-converting enzyme in serum. Clin Chem 1983; 27: 1093-6.
25. Deen WM, Bridges CR, Brenner BM, Myers BD. Heteroporous model of glomerular size selectivity: application to normal and nephrotic humans. Am J Physiol 1985; 249: F374-89.
26. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res 1980; 47: 1-9.
27. Pocock SJ. Clinical trials. A practical approach. Chichester: John Wiley & Sons, 1983: 123-41.
28. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993; 35: 240-7.
29. Chan DP, Sandok EK, Aarhus LL, Heublin DM, Burnett JCJ. Renal-specific actions of the angiotensin II receptor antagonism in the anesthetized dog. Am J Hypertens 1992; 5: 354-60.
30. Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL. Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man. J Cardiovasc Pharmacol 1993; 21: 732-8.
31. Burnier M, Rutscmann B, Versaggi J, Shahinfar S, Waeber B, Brunner HR. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993; 22: 339-47.
32. Skøtt PO, Briggs JP. Direct demonstration of macula densa-mediated renin secretion. Science (Washington DC) 1987; 237: 1618-20.
33. Liu F-Y, Cogan MG. Angiotensin II stimulation of hydrogen ion secretion in the rat early proximal tubule. J Clin Invest 1988; 82: 601-7.
34. Cogan MG, Liu F, Wong PC, Timmermans PBMWM. Comparison of inhibitory potency by nonpeptide angiotensin II receptor antagonists PD123177 and DuP753 on proximal nephron and renal transport. J Pharmacol Exp Ther 1991; 259: 687-91.
35. Terada Y, Tomita K, Nonoguchi H, Marumo F. PCR localization of angiotensin II receptor and angiotensinogen mRNAs in rat kidney. Kidney Int 1993; 43: 1251-9.
36. Romero JC, Knox FG. Mechanisms underlying pressure-related natriuresis: the role of the renin-angiotensin and prostaglandin systems. Hypertension 1988; 11: 724-38.
37. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP 3174, an active metabolite of DUP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 255: 211-17.
38. Sweet CS, Bradstreet DC, Berman SR. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7: 1035-40.
39. Weber MA. Clinical experience with the angiotensin II receptor antagonist losartan: a preliminary report. Am J Hypertens 1992; 5 (Suppl.): 247-51S.
40. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990; 85: 541-9.
41. Remuzzi A, Perico N, Amuchastegui CS, et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993; 4: 40-9.
42. Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 545-50.